• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Pyxis Oncology Inc.

    3/23/26 4:05:06 PM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PYXS alert in real time by email
    S-8 1 pyxs-20260323.htm S-8 S-8

    As filed with the Securities and Exchange Commission on March 23, 2026

     

    Registration No. 333-

     

     

     

    UNITED STATES

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM S-8

     

    REGISTRATION STATEMENT

    UNDER

     

    THE SECURITIES ACT OF 1933

     

     

     

    PYXIS ONCOLOGY, INC.

     

    (Exact name of registrant as specified in its charter)

     

     

    Delaware

    83-1160910

    (State or other jurisdiction of

    incorporation or organization)

    (I.R.S. Employer

    Identification No.)

    321 Harrison Avenue
    Boston, Massachusetts

    02118

    (Address of principal executive offices)

    (Zip Code)

     

    Pyxis Oncology, Inc. 2021 Equity and Incentive Plan, as amended

    Apexigen, Inc. 2022 Equity Incentive Plan

     

    (Full title of the plan)

     

    Jitendra Wadhane

     

    Principal Financial and Accounting Officer

    321 Harrison Avenue
    Boston, Massachusetts

     

     

    (617) 453-3596

     

    (Name, address, and telephone number, including area code, of agent for service)

     

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

     

     

     

     

    Emerging growth company

     

    ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒

     

     


     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 is being filed for the purpose of registering (a) an additional 3,134,511 shares of common stock, par value $0.001 per share (the “Common Stock”), of Pyxis Oncology, Inc., a Delaware corporation (the “Company” or the “Registrant”), to be issued pursuant to the Pyxis Oncology, Inc. 2021 Equity and Incentive Plan, as amended (the “2021 Plan”), which Common Stock is in addition to the shares of Common Stock registered on the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission (the “Commission”) on October 22, 2021 (File No. 333-260441), March 29, 2022 (File No. 333-263950), March 22, 2023 (File No. 333-270753), March 22, 2024 (File No. 333-278159), November 12, 2024 (File No. 333-283161) and March 18, 2025 (File No. 333-285889) (b) 540,703 additional shares of Common Stock available for issuance under the Apexigen, Inc. 2022 Equity Incentive Plan (the “2022 Plan”), which Common Stock is in addition to the shares of Common Stock registered on the Registrant’s Registration Statement on Form S-8 filed with the Commission on August 23, 2023 (File No. 333-274178), March 22, 2024 (File No. 333-278159) and March 18, 2025 (File No. 333-285889) (collectively, the “Prior Form S-8s”).

     

    This Registration Statement on Form S-8 relates to securities of the same class as that to which the Prior Form S-8s relate, and is submitted in accordance with General Instruction E to Form S-8 regarding Registration of Additional Securities. Pursuant to General Instruction E of Form S-8, the contents of the Prior Form S-8s, to the extent relating to the registration of Common Stock issuable under the 2021 Plan and 2022 Plan, as applicable, are incorporated herein by reference and made part of this Registration Statement on Form S-8, except as amended hereby.

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The Registrant hereby incorporates by reference in this Registration Statement the following documents and information previously filed with the Commission:

     

    1.
    The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Commission on March 23, 2026;
    2.
    The Registrant’s Current Report on Form 8-K filed with the SEC on February 6, 2026 except for any information not deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”); and
    3.
    The description of the Registrant’s Common Stock contained in the Registrant’s Registration Statement on Form 8-A, filed with the Commission on October 5, 2021, and any other amendment or report filed for the purpose of updating such description, including Exhibit 4.1 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the Commission on March 22, 2023.

     

    All documents subsequently filed by the Registrant with the Commission pursuant to Sections 13(a), 13(c), 14, and 15(d) of the Securities Exchange Act of 1934, as amended, prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the respective dates of filing of such documents (such documents, and the documents enumerated above, being hereinafter referred to as “Incorporated Documents”).

     

    Any statement contained herein or in an Incorporated Document shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed Incorporated Document modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    Notwithstanding the foregoing, unless specifically stated to the contrary, none of the information disclosed by the Registrant under Items 2.02 or 7.01 of any Current Report on Form 8-K, including the related exhibits under Item 9.01, that the Registrant may from time to time furnish to the Commission will be incorporated by reference into, or otherwise included in, this Registration Statement.

     

     


     

    Item 8. Exhibits.

     

    The following exhibits are incorporated herein by reference:

     

    Exhibit

    Description

     

    No.

     

    4.1

     

    Amended and Restated Certificate of Incorporation of Pyxis Oncology, Inc. (filed as Exhibit 3.1 to Quarterly Report on Form 10-Q with the Securities and Exchange Commission on November 15, 2021 and incorporated herein by reference)

     

    4.2

     

    Amended and Restated Bylaws of Pyxis Oncology, Inc. (filed as Exhibit 3.2 to Quarterly Report on Form 10-Q with the Securities and Exchange Commission on November 15, 2021 and incorporated herein by reference)

     

    4.3

     

    Pyxis Oncology, Inc. 2021 Equity and Incentive Plan (previously filed as Exhibit 4.4 to the Registrant’s Registration Statement on Form S-8, filed with the Commission on October 22, 2021 and incorporated herein by reference)

     

    4.4

     

    First Amendment to Pyxis Oncology, Inc. 2021 Equity and Incentive Plan (previously filed as Appendix A-1 to the Registrant's Definitive Proxy Statement on Schedule 14A, filed with the Commission on September 25, 2024, and incorporated herein by reference)

     

    4.5

     

    Apexigen, Inc. 2022 Equity Incentive Plan (previously filed as Exhibit 4.5 to the Registrant's Registration Statement on Form S-8, filed with the Commission on August 23, 2023 and incorporated herein by reference)

     

    5.1*

     

    Opinion of Sidley Austin LLP with respect to the validity of issuance of securities

     

    23.1*

     

    Consent of Sidley Austin LLP (included in Exhibit 5.1)

     

    23.2*

     

    Consent of Independent Registered Public Accounting Firm

     

    24.1*

     

    Powers of Attorney (included on the signature page of the Registration Statement)

     

    107*

     

    Filing Fee Table

     

    *
    Filed herewith.

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boston, State of Massachusetts, on March 23, 2026.

    Pyxis Oncology, Inc.

    By:

    /s/ Thomas Civik

    Thomas Civik

    Interim Chief Executive Officer

    (Principal Executive Officer)

     

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Thomas Civik and Jitendra Wadhane and each of them, as such person’s true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for such person and in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this this Registration Statement and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or such person’s substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Name

    Title

    Date

    /s/ Thomas Civik

    Interim Chief Executive Officer, Director

    March 23, 2026

    Thomas Civik

    (Principal Executive Officer)

    /s/ Jitendra Wadhane

     

    Principal Financial and Accounting Officer

     

    March 23, 2026

    Jitendra Wadhane

     

    (Principal Financial and Accounting Officer)

     

     

     

     

     

     

     

    /s/ John Flavin

    Chairman of the Board of Directors

    March 23, 2026

    John Flavin

    /s/ Darren Cline

     Director

    March 23, 2026

    Darren Cline

    /s/ Freda Lewis-Hall, M.D.

     Director

    March 23, 2026

    Freda Lewis-Hall, M.D.

    /s/ Rachel Humphrey, M.D.

     Director

    March 23, 2026

    Rachel Humphrey, M.D.

     

     

     

     

     

    /s/ Jakob Dupont, M.D.

     

     Director

     

    March 23, 2026

    Jakob Dupont, M.D.

     

     

     

     

     

     

     

     

     

    /s/ Santhosh Palani, Ph.D., CFA

     

    Director

     

    March 23, 2026

    Santhosh Palani, Ph.D., CFA

     

     

     

     

     

     

     

     

     

    /s/ Michael A. Metzger

     

    Director

     

    March 23, 2026

    Michael A. Metzger

     

     

     

     

     

     

     

     

     

    /s/ Lara Sullivan M.D.

     

    Director

     

    March 23, 2026

     

    Lara Sullivan, M.D.

     

     

     

     

     

     

     


    Get the next $PYXS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PYXS

    DatePrice TargetRatingAnalyst
    11/3/2025$9.00Buy
    Stifel
    9/4/2025$5.00Buy
    Guggenheim
    11/21/2024Outperform → Mkt Perform
    William Blair
    11/8/2024$13.00Overweight
    Stephens
    8/8/2024$10.00Buy
    Stifel
    5/7/2024$10.00Buy
    Jefferies
    2/9/2024$8.00Buy
    BTIG Research
    1/23/2024$12.00Outperform
    Leerink Partners
    More analyst ratings

    $PYXS
    SEC Filings

    View All

    SEC Form S-8 filed by Pyxis Oncology Inc.

    S-8 - Pyxis Oncology, Inc. (0001782223) (Filer)

    3/23/26 4:05:06 PM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Pyxis Oncology Inc.

    10-K - Pyxis Oncology, Inc. (0001782223) (Filer)

    3/23/26 7:17:26 AM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pyxis Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Pyxis Oncology, Inc. (0001782223) (Filer)

    3/23/26 7:12:28 AM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PYXS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stifel resumed coverage on Pyxis Oncology with a new price target

    Stifel resumed coverage of Pyxis Oncology with a rating of Buy and set a new price target of $9.00

    11/3/25 9:08:29 AM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Pyxis Oncology with a new price target

    Guggenheim initiated coverage of Pyxis Oncology with a rating of Buy and set a new price target of $5.00

    9/4/25 9:07:21 AM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pyxis Oncology downgraded by William Blair

    William Blair downgraded Pyxis Oncology from Outperform to Mkt Perform

    11/21/24 7:55:42 AM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PYXS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Interim CEO Civik Thomas

    4 - Pyxis Oncology, Inc. (0001782223) (Issuer)

    2/5/26 8:37:38 PM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by President ,CEO & CMO Sullivan Lara

    4 - Pyxis Oncology, Inc. (0001782223) (Issuer)

    4/2/25 9:06:50 AM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Metzger Michael A

    4 - Pyxis Oncology, Inc. (0001782223) (Issuer)

    4/2/25 9:05:43 AM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PYXS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

    Completed target enrollment in Phase 1 monotherapy dose expansion study of micvotabart pelidotin (MICVO) in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) in the first quarter of 2026 Updated data from MICVO Phase 1 monotherapy study in 2L+ R/M HNSCC on track for mid-year 2026; to include patients treated with modified weight-based dosing and patients treated with total body weight dosing Updated data from MICVO Phase 1/2 dose escalation study in combination with KEYTRUDA® in 1L/2L+ R/M HNSCC on track for the second half of 2026 Announced appointment of Thomas Civik as Interim Chief Executive Officer Expected cash runway into the fourth quarter of 2026 BOSTO

    3/23/26 7:00:00 AM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity

    BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a leadership transition to continue execution and advancement of the Company's strategic and clinical goals. Thomas Civik, a member of Pyxis Oncology's Board of Directors since the Company's IPO and a highly experienced biotechnology executive with a proven track record in advancing cancer therapeutics, has been appointed Interim Chief Executive Officer, effective immediately. Lara S. Sullivan, M.D., has stepped down from her roles as President, Chief Executive Officer and Chief Medical Officer. With

    2/3/26 6:45:00 AM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff

    VANCOUVER, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The biotechnology sector is entering a high-stakes survival sprint as major pharmaceutical giants confront a looming $170 billion patent cliff[1]. This massive pressure is forcing a strategic capital rotation toward late-stage, registration-ready oncology platforms that can be delivered with biologic-like manufacturing efficiency. With blockbuster drugs losing exclusivity through 2030, the precision oncology market is projected to reach $225.65 billion by 2032[2] as buyers aggressively target scalable technologies. This industry-wide shift into proprietary precision platforms fuels the 2026

    1/12/26 10:14:09 AM ET
    $ALLO
    $CHRS
    $ELVN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $PYXS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CFO & COO Connealy Pamela Ann bought $174,364 worth of shares (88,850 units at $1.96) (SEC Form 4)

    4 - Pyxis Oncology, Inc. (0001782223) (Issuer)

    11/27/24 5:09:59 PM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Connealy Pamela Ann bought $14,960 worth of shares (8,000 units at $1.87), increasing direct ownership by 0.99% to 818,532 units (SEC Form 4)

    4 - Pyxis Oncology, Inc. (0001782223) (Issuer)

    9/28/23 4:32:03 PM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wadhane Jitendra bought $4,675 worth of shares (2,500 units at $1.87), increasing direct ownership by 1% to 226,937 units (SEC Form 4)

    4 - Pyxis Oncology, Inc. (0001782223) (Issuer)

    9/27/23 6:37:45 PM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PYXS
    Leadership Updates

    Live Leadership Updates

    View All

    Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

    Completed target enrollment in Phase 1 monotherapy dose expansion study of micvotabart pelidotin (MICVO) in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) in the first quarter of 2026 Updated data from MICVO Phase 1 monotherapy study in 2L+ R/M HNSCC on track for mid-year 2026; to include patients treated with modified weight-based dosing and patients treated with total body weight dosing Updated data from MICVO Phase 1/2 dose escalation study in combination with KEYTRUDA® in 1L/2L+ R/M HNSCC on track for the second half of 2026 Announced appointment of Thomas Civik as Interim Chief Executive Officer Expected cash runway into the fourth quarter of 2026 BOSTO

    3/23/26 7:00:00 AM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity

    BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a leadership transition to continue execution and advancement of the Company's strategic and clinical goals. Thomas Civik, a member of Pyxis Oncology's Board of Directors since the Company's IPO and a highly experienced biotechnology executive with a proven track record in advancing cancer therapeutics, has been appointed Interim Chief Executive Officer, effective immediately. Lara S. Sullivan, M.D., has stepped down from her roles as President, Chief Executive Officer and Chief Medical Officer. With

    2/3/26 6:45:00 AM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets

    BOSTON, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing antibody-drug conjugate (ADC) therapeutics for difficult-to-treat cancers, today announced the appointment of Alex Kane, MBA, as Senior Vice President, Investor Relations & Capital Markets, effective immediately. Mr. Kane brings 20 years of experience and a proven track record in investor relations, strategic communications, and equity capital markets across the life sciences sector. He joins Pyxis Oncology from Guggenheim Securities, where he served as Vice President of Equity Capital Markets, advising biotechnology clients on financing strategies and equity transactions. Pr

    10/9/25 7:30:00 AM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PYXS
    Financials

    Live finance-specific insights

    View All

    Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

    46% confirmed objective response rate (ORR) and 92% disease control rate (DCR) observed with MICVO as monotherapy in 2L+ R/M HNSCC at 5.4 mg/kg 71% confirmed ORR and 100% DCR observed with MICVO in combination with KEYTRUDA® (pembrolizumab) in 1L/2L+ R/M HNSCC at 3.6 mg/kg and 4.4 mg/kgUpdated data from ongoing Phase 1 monotherapy study in 2L+ R/M HNSCC expected mid-2026; updated data from ongoing Phase 1/2 study evaluating MICVO in combination with KEYTRUDA®, including in 1L/2L+ R/M HNSCC and other tumor types, expected 2H26 Company to host webcast and conference call today at 8:30 a.m. ET BOSTON, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage comp

    12/18/25 7:00:00 AM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024

    - Preliminary data from the first-in-patient Phase 1 dose escalation trial of PYX-201 to be announced at upcoming virtual and in-person event in New York City on Wednesday, November 20, 2024, at 4:30 p.m. ET - Preliminary data from the Phase 1 trial of PYX-106 is expected to be reported by year-end 2024 - Expected cash runway into 2H 2026 BOSTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today reported financial results for the third quarter ended September 30, 2024, and provided a corporate update. The Company ended the third quarter of 20

    11/12/24 7:30:00 AM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024

    - Preliminary data from the Phase 1 trial of PYX-201 remains on track to be announced in the fall of 2024 - Preliminary data from the Phase 1 trial of PYX-106 is expected to be reported by year-end 2024 - Expected cash runway into 2H 2026 BOSTON, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today reported financial results for the second quarter ended June 30, 2024, and provided a corporate update. The Company ended the second quarter of 2024 with $157.2 million in cash, cash equivalents, restricted cash and short-term investments, which is expected

    8/14/24 4:05:00 PM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PYXS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Pyxis Oncology Inc.

    SC 13G/A - Pyxis Oncology, Inc. (0001782223) (Subject)

    11/12/24 11:53:51 AM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Pyxis Oncology Inc.

    SC 13G/A - Pyxis Oncology, Inc. (0001782223) (Subject)

    11/6/24 4:36:24 PM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Pyxis Oncology Inc. (Amendment)

    SC 13D/A - Pyxis Oncology, Inc. (0001782223) (Subject)

    4/3/24 5:10:59 PM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care